In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PainCeptor Pharma Corp.

www.painceptor.com

Latest From PainCeptor Pharma Corp.

Novel Pain Therapeutics: When Will Life Get Better On The Island Of Pain?

Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.
BioPharmaceutical

Market Insight - A fresh look at ion channels

Mark Greener reviews a selection of ion channels currently attracting researchers' attention, demonstrating renewed interest in the clinical and commercial potential of an underexploited therapeutic target

Gastrointestinal Metabolic Disorders

Cara Therapeutics Inc.

Given the paucity of novel pain drugs and the calamities surrounding Vioxx and OxyContin, Big Pharma has a keen interest in finding alternatives. Working within the G-protein coupled receptor superfamily, Cara Therapeutics hopes to oblige.
Research and Development Strategies

Start-Up Previews (9/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile groups: GI Drug Development: AGI Therapeutics, Napo Pharmaceuticals, Tioga Pharmaceuticals. Plus these Start-Ups across Health Care: Cierra, PainCeptor, Tengion, TyRx Pharma.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • PainCeptor Pharma Corp.
  • Senior Management
  • Louis R Lamontagne, PhD, Pres. & CEO
    Francine Gervais, PhD, SVP & VP, Pharmaceutical Dev.
    Kazimierz Babinski, VP, Res.
    Marcus Brady, VP, Bus. Dev.
  • Contact Info
  • PainCeptor Pharma Corp.
    Phone: (514) 337-5959
    7150, Albert-Einstein, Ste. 100
    Saint-Laurent
    Montreal, H4S 2C1
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register